Sign in Subscribe

article

A collection of 632 issues

Adding Chemotherapy to Immunotherapy May Extend Survival in MSI-H Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Adding Chemotherapy to Immunotherapy May Extend Survival in MSI-H Metastatic CRC The phase III NRG-GI004/SWOG S1610 COMMIT trial found that combining mFOLFOX6, bevacizumab, and atezolizumab may prolong progression-free survival over atezolizumab alone in first-line treatment of mismatch repair–deficient/microsatellite instability–

FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults

Skip to content The CRC Digest ● REGULATORY FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults The FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 and older at average risk, based on data from the PREEMPT CRC trial. (The ASCO Post)

Sports Team Branding on Mailed Screening Kits Tested as Engagement Strategy

Skip to content The CRC Digest ▪ SCREENING Sports Team Branding on Mailed Screening Kits Tested as Engagement Strategy A randomized quality improvement study examined whether adding sports team branding and discount incentives to mailed colorectal cancer screening kits improved screening uptake. (Gastroenterology and Hepatology Advances) This content is informational only

Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC Trials

Skip to content The CRC Digest ◆ TRIAL DATA Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC Trials Researchers used the ARCAD database to construct external control arms from historical trial data for seven landmark metastatic colorectal cancer trials, evaluating whether this approach could complement traditional

Genetic Changes Between Primary and Recurrent Rectal Cancer May Reveal New Treatment Targets

Skip to content The CRC Digest ◇ RESEARCH Genetic Changes Between Primary and Recurrent Rectal Cancer May Reveal New Treatment Targets A study of 15 matched pairs of primary and locally recurrent rectal cancers found that recurrent tumors acquired new genetic alterations not present in the original tumor, including potentially actionable

Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy Researchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer) This

Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery

Skip to content The CRC Digest ◆ TRIAL DATA Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery A phase Ib trial evaluated the safety of combining trifluridine/tipiracil chemotherapy with radiation therapy before surgery in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)

Amino-acid biomarkers studied for Lynch syndrome surveillance

Skip to content The CRC Digest Amino-acid biomarkers studied for Lynch syndrome surveillance A prospective study is evaluating whether faecal and urinary amino-acids can help refine colonoscopy surveillance in individuals with Lynch syndrome, potentially reducing the burden of frequent screening. (International Journal of Cancer) This content is informational only and

Chemotherapy rechallenge shows activity in late-line metastatic disease

Skip to content The CRC Digest ◆ TRIAL DATA Chemotherapy rechallenge shows activity in late-line metastatic disease A phase II trial found that patients with refractory metastatic colorectal cancer who had previously responded to a regimen for at least 4 months could benefit from rechallenge with the same chemotherapy, with or

PharmFIT trial tests pharmacy-based colorectal cancer screening

Skip to content The CRC Digest ▪ SCREENING PharmFIT trial tests pharmacy-based colorectal cancer screening A two-arm, pragmatic, hybrid type 1 effectiveness-implementation trial is underway in Washington and North Carolina to evaluate whether community pharmacies can expand access to FIT screening for underserved patients due for colorectal cancer screening. (Contemporary Clinical